NCT02210624 is a NA clinical trial of HYNR-CS inj. in Anoxic Brain Injury, sponsored by Hyun Young Kim.

Who is sponsoring NCT02210624?

NCT02210624 is sponsored by Hyun Young Kim.

What drugs are being tested in NCT02210624?

Interventions in NCT02210624: HYNR-CS inj..

What condition does NCT02210624 study?

NCT02210624 studies Anoxic Brain Injury.

Is NCT02210624 still recruiting?

NCT02210624 is currently status unknown. Last updated 8 August 2017.

Last reviewed 2017-08-08 · How we verify

NCT02210624

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label, Safety and Efficacy Assessment of Autologous Bone-marrow Derived Mesenchymal Stem Cell Therapy in Anoxic (or Hypoxic) Brain Injury.

Status unknown NA Last updated 8 August 2017

What this trial tests

NA trial testing HYNR-CS inj. in Anoxic Brain Injury in 4 participants. Status unknown.

Timeline

1 March 2013

Primary endpoint
1 December 2018

1 December 2018

Quick facts

Lead sponsor	Hyun Young Kim
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	1 March 2013
Primary completion	1 December 2018
Estimated completion	1 December 2018
Sites	1 location across South Korea

Drugs / interventions tested

HYNR-CS inj.

Conditions studied

Anoxic Brain Injury — all drugs for Anoxic Brain Injury →

Sponsor

Hyun Young Kim

Who can join

Adults 18 to 75, any sex, with Anoxic Brain Injury. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

safety assessment
Time frame: week 1, 3, 4, 5, 7
Each visit physical examination, neurological examination, and adverse reactions through the follow-up to the expression of new symptoms. week 1,3,5,7 conducted Hematological week 4,7 conducted MRI, PET

Sponsor's own description

The purpose of study is to evaluate the safety and efficacy of autologous bone marrow-derived stem cells therapy in patients with anaerobic (hypoxic) brain injury. Stem cell therapy is an emerging alternative treatment modality in incurable and intractable neurological disorders. This pilot study aims to evaluate the feasibility and safety of stem cells in anaerobic brain injury.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Underregistration and Underreporting of Stem Cell Clinical Trials in Neurological Disorders.
Lee TE, Kim A, Jang M, Jeon B. · · 2018 · cited 4× · PMID 29629526 · DOI 10.3988/jcn.2018.14.2.215

Verify or expand the search:

Other recruiting trials for Anoxic Brain Injury

Currently open trials in the same condition.

NCT05004610 — Hypertonic Lactate After Cardiac Arrest · Phase 2 · recruiting
NCT03814356 — Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness · Phase 1 · active not recruiting
NCT03243539 — Implementation of Neuro Lung Protective Ventilation · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02210624 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hyun Young Kim
Last refreshed: 8 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02210624.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing